News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
487,381 Results
Type
Article (8023)
Company Profile (141)
Press Release (479217)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166743)
Career Advice (305)
Deals (25738)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9760)
Job Trends (8574)
News (238195)
Policy (17898)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (495)
Accelerated approval (28)
ADA (18)
Adcomms (1)
Allergies (100)
Alliances (33156)
ALS (116)
Alzheimer's disease (992)
Antibody-drug conjugate (ADC) (308)
Approvals (10447)
Artificial intelligence (352)
ASCO (160)
Autoimmune disease (233)
Automation (32)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6958)
BIO (36)
Biologics (28)
BIOSECURE Act (1)
Biosimilars (123)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (9)
Bladder cancer (141)
Brain cancer (34)
Breast cancer (528)
Cancer (3899)
Cardiovascular disease (235)
Career advice (246)
Career pathing (1)
CAR-T (184)
CDC (1)
CDMO (28)
Celiac Disease (3)
Cell therapy (504)
Cervical cancer (36)
Clinical research (48310)
Collaboration (1335)
Commercialization (20)
Compensation (1599)
Complete response letters (36)
COVID-19 (767)
CRISPR (66)
C-suite (837)
Cystic fibrosis (88)
Data (6177)
Denatured (4)
Depression (108)
Dermatology (93)
Diabetes (377)
Diagnostics (4243)
Digital health (40)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (167)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (174)
Earnings (73835)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88489)
Executive appointments (729)
Eye disease (3)
FDA (12618)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (1)
Friedreich's ataxia (19)
Frontotemporal dementia (25)
Funding (988)
Gene editing (129)
Generative AI (13)
Gene therapy (346)
GLP-1 (305)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9383)
Hematology (94)
HIV (55)
Huntington's disease (25)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (73)
Immunology and inflammation (111)
Immuno-oncology (65)
Indications (175)
Infectious disease (967)
Inflammatory bowel disease (137)
Inflation Reduction Act (4)
Influenza (87)
Intellectual property (269)
Interviews (41)
IPO (12395)
IRA (2)
Job creations (1968)
Job search strategy (236)
JPM (1)
Kidney cancer (17)
Kidney disease (63)
Layoffs (59)
Legal (5195)
Licensing (41)
Liver cancer (46)
Longevity (22)
Lung cancer (561)
Lung diease (8)
Lymphoma (266)
Machine learning (29)
Management (3)
Manufacturing (607)
Marketing (14)
MASH (120)
Medical affairs (2)
Medical device (8706)
Medtech (8880)
Mergers & acquisitions (14442)
Metabolic disorders (757)
mRNA (70)
Multiple sclerosis (110)
Multispecific (2)
NASH (4)
Netherlands (1)
Neurodegenerative disease (236)
Neuropsychiatric disorders (40)
Neuroscience (1917)
Neurotech (1)
NextGen: Class of 2026 (3151)
Non-profit (844)
Now hiring (1)
Obesity (237)
Opinion (10)
Ovarian cancer (175)
Pain (184)
Pancreatic cancer (223)
Parkinson's disease (215)
Partnered (12)
Patents (521)
Patient advocacy (2)
Patient recruitment (547)
Patient selection (33)
Peanut (33)
People (41472)
Peptides (11)
Pharmaceutical (30)
Pharmacy benefit managers (10)
Phase 1 (15591)
Phase 2 (21585)
Phase 3 (14560)
Pipeline (8187)
Policy (18)
Postmarket research (1570)
Preclinical (6576)
Press Release (34)
Prostate cancer (201)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (617)
Real estate (3024)
Recruiting (6)
Regenerative medicine (11)
Regulatory (15126)
Reports (23)
Research institute (590)
Resumes & cover letters (45)
Rett syndrome (45)
RNA editing (8)
RSV (49)
Schizophrenia (108)
Series A (173)
Series B (126)
Service/supplier (5)
Sickle cell disease (64)
Spinal muscular atrophy (92)
Sponsored (5)
Startups (2022)
Stem cells (1)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (54)
Tariffs (1)
Vaccines (344)
Venture capital (17)
Weight loss (76)
Wet AMD (1)
Women's health (95)
Date
Today (111)
Last 7 days (365)
Last 30 days (1514)
Last 365 days (19251)
2026 (15010)
2025 (19251)
2024 (22988)
2023 (26539)
2022 (34588)
2021 (37169)
2020 (33471)
2019 (23256)
2018 (17468)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20440)
2010 (20332)
Location
Africa (231)
Alabama (80)
Alaska (2)
Arizona (317)
Arkansas (12)
Asia (18019)
Australia (2115)
California (12727)
Canada (3329)
China (564)
Colorado (517)
Connecticut (444)
Delaware (220)
Europe (24763)
Florida (1916)
Georgia (403)
Hawaii (3)
Idaho (46)
Illinois (760)
India (57)
Indiana (330)
Iowa (17)
Japan (444)
Kansas (104)
Kentucky (33)
Louisiana (27)
Maine (27)
Maryland (1258)
Massachusetts (8321)
Michigan (320)
Minnesota (588)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (130)
New Hampshire (60)
New Jersey (2800)
New Mexico (12)
New York (2985)
North Carolina (1349)
North Dakota (4)
Northern California (6433)
Ohio (301)
Oklahoma (14)
Oregon (16)
Pennsylvania (2365)
Puerto Rico (24)
Rhode Island (30)
South America (407)
South Carolina (80)
South Dakota (1)
Southern California (5302)
Tennessee (128)
Texas (2100)
United States (41242)
Utah (386)
Vermont (1)
Virginia (162)
Washington D.C. (39)
Washington State (979)
West Virginia (1)
Wisconsin (81)
Wyoming (1)
487,381 Results for "locanabio inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Locanabio Announces Participation in Chardan’s 7th Annual Genetic Medicines Conference
Locanabio, Inc. today announced that Jim Burns, Ph.D., Locanabio’s chief executive officer, will provide a corporate overview at 5:30 pm. ET on Monday, October 2nd at Chardan’s 7th Annual Genetic Medicines Conference which is being held in New York City.
September 25, 2023
·
1 min read
Drug Development
Locanabio Announces Presentation of Preclinical Data Demonstrating an Improved Vectorized snRNA Platform
Locanabio, Inc. today announced the presentation of data demonstrating the packaging and delivery of its proprietary small nuclear RNA (snRNA) platform using adeno-associated virus (AAV).
October 6, 2023
·
5 min read
Biotech Beach
Locanabio Announces Equity Investment from CureDuchenne Ventures to Support Development of snRNA Exon Skipping Approach for Duchenne Muscular Dystrophy (DMD)
Locanabio, Inc., a genetic medicines company developing RNA-targeted therapeutics for patients with rare genetic neuromuscular and neurodegenerative diseases, announced that CureDuchenne Ventures, the strategic investment arm of CureDuchenne, has made an equity investment in Locanabio.
May 15, 2023
·
4 min read
Biotech Beach
Locanabio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Locanabio, Inc. today announced that data from LBIO-115, its vectorized snRNA exon skipping program in development for the treatment of Duchenne muscular dystrophy (DMD) with mutations amenable to exon 51 skipping, and its Cas13d-mediated program for C9orf72-related amyotrophic lateral sclerosis (ALS) will be presented at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
May 2, 2023
·
2 min read
Biotech Beach
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
Locanabio, Inc. announced the first presentation of data from its next generation engineered small nuclear RNA, or snRNA, platform, which is designed to efficiently deliver targeted snRNA payloads via an adeno-associated virus for long-term therapeutic expression.
April 20, 2023
·
5 min read
Drug Development
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
Locanabio, Inc. announced the presentation of data from its lead vectorized snRNA exon skipping program, LBIO-115, in development for the treatment of Duchenne muscular dystrophy.
May 16, 2023
·
7 min read
Biotech Beach
Locanabio to Participate in Upcoming Investor Conferences - Nov 22, 2021
Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, announced that its leadership team will participate in the following upcoming investor conferences.
November 22, 2021
·
1 min read
Business
Locanabio Expands Leadership Team with Appointment of Kat Lange as Chief Financial Officer
Locanabio, Inc. today announced the appointment of Kat Lange as chief financial officer.
September 7, 2021
·
2 min read
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Biotech Beach
Locanabio to Present at 40th Annual J.P. Morgan Healthcare Conference
Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that Jim Burns, PhD, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:30 a.m. ET.
January 4, 2022
·
1 min read
1 of 48,739
Next
